Stemline Therapeutics, Inc.
(NASDAQ : STML)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -3.96%58.190.0%$1899.37m
REGNRegeneron Pharmaceuticals, Inc. -0.26%597.002.5%$1174.48m
GILDGilead Sciences, Inc. -1.02%76.751.0%$975.82m
AMGNAmgen, Inc. 2.17%225.671.3%$660.44m
NVAXNovavax, Inc. 3.67%46.30102.0%$655.72m
VRTXVertex Pharmaceuticals, Inc. -2.61%265.691.9%$544.78m
ILMNIllumina, Inc. -1.20%354.113.5%$388.06m
BIIBBiogen, Inc. 2.36%306.721.6%$378.26m
SRNESorrento Therapeutics, Inc. 6.74%4.121.8%$269.11m
ALXNAlexion Pharmaceuticals, Inc. 1.35%115.212.0%$241.70m
SGENSeattle Genetics, Inc. -1.36%148.396.1%$223.95m
AAgilent Technologies, Inc. -0.83%90.381.6%$215.81m
BMRNBioMarin Pharmaceutical, Inc. -1.59%105.804.3%$184.97m
SRPTSarepta Therapeutics, Inc. 2.06%147.9913.9%$156.63m
INCYIncyte Corp. -0.31%93.512.5%$153.41m

Company Profile

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.